Quarterly ResultMay 12, 2026, 04:18 PM
TherapeuticsMD Q1 Net Income $103K; Revenue +$331K
AI Summary
TherapeuticsMD reported a net income from continuing operations of $103 thousand for Q1 2026, a significant improvement from a $636 thousand net loss in Q1 2025. License revenue increased by $331 thousand to $724 thousand, driven by higher sales of licensed products. Total operating expenses decreased by 13.6% to $1.447 million. The company continues to evaluate strategic alternatives, including potential acquisitions, mergers, or asset sales.
Key Highlights
- Net income from continuing operations was $103 thousand in Q1 2026, up from a $636 thousand net loss in Q1 2025.
- License revenue from continuing operations increased by $331 thousand to $724 thousand in Q1 2026.
- Total operating expenses decreased by 13.6% to $1.447 million in Q1 2026.
- The company continues to evaluate strategic alternatives, including mergers, acquisitions, or asset sales.
- Cash and cash equivalents totaled $8.4 million as of March 31, 2026.